Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GNC-039 by Systimmune for Solid Tumor: Likelihood of Approval
GNC-039 is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Data Insights
GNC-039 by Systimmune for High-Grade Glioma: Likelihood of Approval
GNC-039 is under clinical development by Systimmune and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I...